Digital Therapeutix provides digital health solutions that enable laboratories to deploy phage-based therapies for bacterial infections. The company's focus is on combating antibiotic resistance in clinical, veterinary, and agricultural sectors by ensuring equitable access to these targeted treatments.
Funding
Funding not disclosed
Founders
Product
Problem
The rise of antibiotic-resistant bacteria poses a significant threat to human and animal health, requiring new approaches to combat infections. Current reliance on broad-spectrum antibiotics often leads to the development of resistance, disrupting the microbiome and limiting treatment options. There is a need for targeted therapies that can selectively eliminate pathogenic bacteria without harming beneficial flora.
Solution
Digital Therapeutix is developing solutions that enable the deployment of phage-based therapies to combat bacterial infections in clinical, veterinary, and agricultural settings. Their approach leverages bacteriophages, naturally occurring viruses that selectively target and kill specific bacteria, as an alternative to traditional antibiotics. By providing access to these targeted treatments, Digital Therapeutix aims to reduce the reliance on broad-spectrum antibiotics and mitigate the spread of antibiotic resistance. Their solutions are designed to ensure equitable access to phage-based therapies across various sectors, addressing the growing need for effective and sustainable antimicrobial strategies.
Target Audience
The primary target audience includes laboratories, healthcare providers, veterinarians, and agricultural businesses seeking alternatives to traditional antibiotics for combating bacterial infections.
Features
- Phage-based therapies targeting specific bacterial pathogens
- Solutions for clinical applications in human health
- Veterinary applications for animal health
- Agricultural applications for crop protection